Alpha-1 Biologics

Alpha-1 Biologics is a pre-clinical stage biotech leveraging foundational research from its founder, Dr. Cynthia L. Bristow, to develop oral therapies that modulate immune cell trafficking. The company's core technology aims to generate immune cells from stem cells within the body, targeting significant unmet needs in cancer immunotherapy and primary/secondary immunodeficiencies. It has been historically funded by non-profit research organizations but appears to be a private, early-stage venture with a pipeline yet to enter clinical trials. The leadership brings deep academic and clinical immunology expertise, though the company's operational scale and recent funding trajectory are not publicly detailed.

Platform focused on orally available small molecules designed to stimulate the locomotion and potentially the in vivo generation of Helper T cells and pre-T cells from stem/progenitor populations for immune reconstitution and metabolic regulation.

In immunotherapy, competes with large pharma and biotech companies developing injectable biologics, cell therapies, and cytokines for immune reconstitution. In cardiovascular, faces entrenched players with statins, PCSK9 inhibitors, and emerging RNA-based therapies. Its proposed oral, small-molecule immunomodulator is a distinct approach, but it lacks the clinical validation of established modalities.